These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11103052)

  • 1. Increase of atherogenic plasma profile in HIV-infected patients treated with protease inhibitor-containing regimens.
    Bonnet F; Savès M; Droz C; Peuchant E; Chêne G; Beylot J; Morlat P
    J Acquir Immune Defic Syndr; 2000 Oct; 25(2):199-200. PubMed ID: 11103052
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients.
    Doser N; Kübli S; Telenti A; Marzolini C; Chave JP; Feihl F; Buclin T; Pannatier A; Darioli R; Nicod P; Waeber B; Mooser V
    AIDS; 2002 Sep; 16(14):1982-3. PubMed ID: 12351967
    [No Abstract]   [Full Text] [Related]  

  • 3. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.
    Périard D; Telenti A; Sudre P; Cheseaux JJ; Halfon P; Reymond MJ; Marcovina SM; Glauser MP; Nicod P; Darioli R; Mooser V
    Circulation; 1999 Aug; 100(7):700-5. PubMed ID: 10449690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.
    Manfredi R; Chiodo F
    J Infect; 2001 Apr; 42(3):181-8. PubMed ID: 11545549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART.
    Calza L; Manfredi R; Chiodo F
    AIDS; 2003 Apr; 17(6):851-9. PubMed ID: 12660532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small dense LDL and atherogenic lipid profile in HIV-positive adults: influence of lopinavir/ritonavir-containing regimen.
    Badiou S; De Boever CM; Dupuy AM; Baillat V; Cristol JP; Reynes J
    AIDS; 2003 Mar; 17(5):772-4. PubMed ID: 12646808
    [No Abstract]   [Full Text] [Related]  

  • 7. [Hyperlipidemia in patients with HIV infection treated with protease inhibitors].
    López García F; Mora Rufete A; Escolano Hortelano CM; Gutiérrez Rodero F
    Rev Clin Esp; 1999 Nov; 199(11):780-1. PubMed ID: 10638253
    [No Abstract]   [Full Text] [Related]  

  • 8. Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1-positive patients.
    Hewitt RG; Shelton MJ; Esch LD
    AIDS; 1999 May; 13(7):868-9. PubMed ID: 10357393
    [No Abstract]   [Full Text] [Related]  

  • 9. Rhabdomyolysis after cerivastatin-gemfibrozil therapy in an HIV-infected patient with protease inhibitor-related hyperlipidemia.
    Mastroianni CM; d'Ettorre G; Forcina G; Lichtner M; Corpolongo A; Coletta S; Vullo V
    AIDS; 2001 Apr; 15(6):820-1. PubMed ID: 11371708
    [No Abstract]   [Full Text] [Related]  

  • 10. "Buffalo hump" in HIV-1 infection.
    Stocker DN; Meier PJ; Stoller R; Fattinger KE
    Lancet; 1998 Jul; 352(9124):320-1. PubMed ID: 9690434
    [No Abstract]   [Full Text] [Related]  

  • 11. The effects of antiretroviral protease inhibitors on serum lipid levels in HIV-infected patients.
    Chang ES; Tetreault DD; Liu YT; Beall GN
    J Am Diet Assoc; 2001 Jun; 101(6):687-9. PubMed ID: 11424549
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of protease inhibitors on apolipoprotein B levels and plasma lipid profile in HIV-1-infected patients on highly active antiretroviral therapy.
    Domingo P; Sambeat MA; Pérez A; Ordoñez J
    J Acquir Immune Defic Syndr; 2003 May; 33(1):114-6. PubMed ID: 12792364
    [No Abstract]   [Full Text] [Related]  

  • 13. Vascular complications associated with use of HIV protease inhibitors.
    Gallet B; Pulik M; Genet P; Chedin P; Hiltgen M
    Lancet; 1998 Jun; 351(9120):1958-9. PubMed ID: 9654285
    [No Abstract]   [Full Text] [Related]  

  • 14. HIV protease inhibitors and hyperlipidemia: a fatty acid connection.
    Spector AA
    Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):7-9. PubMed ID: 16373621
    [No Abstract]   [Full Text] [Related]  

  • 15. Lipid abnormalities associated with protease inhibitors.
    Melroe NH; Kopaczewski J; Henry K; Huebsch J
    J Assoc Nurses AIDS Care; 1999; 10(2):22-30. PubMed ID: 10065407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy.
    Lainka E; Oezbek S; Falck M; Ndagijimana J; Niehues T
    Pediatrics; 2002 Nov; 110(5):e56. PubMed ID: 12415062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperlipidemia associated with the use of protease inhibitors.
    Smith JH; Martin GJ; Decker CF
    Clin Infect Dis; 2000 Jul; 31(1):207-8. PubMed ID: 10913432
    [No Abstract]   [Full Text] [Related]  

  • 18. Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study.
    Calza L; Colangeli V; Manfredi R; Legnani G; Tampellini L; Pocaterra D; Chiodo F
    AIDS; 2005 Jul; 19(10):1103-5. PubMed ID: 15958843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Myocardial infarction in the course of antiretroviral therapy with protease inhibitor].
    Buccoliero G; Lonero G; Rollo MA; Cristiano L; Romanelli C; Loperfido P; Chimienti A; Angelini P; Resta F
    Recenti Prog Med; 2003 Jun; 94(6):264-6. PubMed ID: 12793098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment.
    Penzak SR; Chuck SK
    Scand J Infect Dis; 2000; 32(2):111-23. PubMed ID: 10826894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.